Details

October 28, 2021

Zoom Online

Event Summary:

Anticholinergics and Dementia: Time for Action?

• Associations between the prescription anticholinergics and development of dementia have been recognised for many years but little action has occurred because of uncertainty as to whether (certain) anticholinergics cause dementia. Applying the Bradford-Hill criteria for causation to the evidence base, there is now compelling evidence of a causal link, particularly for oxybutynin.

• Pharmacists have a key role in identifying anticholinergic prescribing in older people, and the use of anticholinergic burden scales can be helpful in doing this.

• Now is the time to act on reducing the risks of dementia from anticholinergics, and pharmacists have a crucial role in educating prescribers, working with other clinicians to address anticholinergic burden, and influencing policymakers at local and national level

PCPA provide all sponsors/exhibitors with a full delegate list. This includes name, job title and county and does not contain any contact details. By registering for this event, you are in agreement with this information to be shared in a closed environment.

Please read the PCPA Privacy Policy here

Please read the PCPA Disclaimer here